Gilead Sciences, Inc. GILD announced that the FDA has granted accelerated approval to Hepcludex (bulevirtide-gmod) for adults with chronic hepatitis delta virus (HDV) infection. The approval makes ...

The trial failure reinforces Keytruda’s competitive position in first-line metastatic melanoma, where it already outperformed ...

Krystal Biotech is the furthest along in pursuing this approach and is ironing out details of a registrational trial for its ...

Treatment with the TROP2 ADC sac-TMT led to a 70% objective response rate and progression-free survival was “significantly ...

Merck (MRK) stock gains as a cancer drug the company develops with Kelun-Biotech bests its Keytruda blockbuster in a ...

Adding Inhibrx Biosciences’ OX40 agonist to Keytruda doubled the response rate in a midphase clinical trial, encouraging the biotech to advance a program that reportedly attracted the interest of ...

The late-stage miss shakes analyst confidence in Regeneron’s clinical execution, according to BMO Capital Markets, also ...

Merck reported higher first-quarter sales and raised its full-year earnings guidance as demand for its flagship Keytruda cancer drug continues to grow. Sales rose 5% to $16.29 billion, boosted by 12% ...

Health Minister Mike Nesbitt has confirmed that a key injectable cancer drug which can be used to treat multiple cancers is being used in three of Northern Ireland's five health trusts. Pembrolizumab ...

The NHS in East Yorkshire and North Lincolnshire is among the first in the UK to offer an injectable form of Keytruda, reducing treatment time from over an hour to just minutes. The change is expected ...

The drug is normally received by patients through a drip which can take more than an hour in hospital, but injectables are quicker and less intrusive Health Minister Mike Nesbitt has confirmed that a ...